✦ LIBER ✦

The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptor

✍ Scribed by Inhye E. Ahn; Ji Hyeon Ju; Kwi Young Kang; Sung-Hwan Park; Ho-Youn Kim

Publisher: Springer
Year: 2009
Tongue: English
Weight: 287 KB
Volume: 29
Category: Article
ISSN: 0770-3198
DOI: 10.1007/s10067-009-1306-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Association between serum levels of solu

Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy : A Gynecologic Oncology Group study

✍ Robert A. Burger; Kathleen M. Darcy; Philip J. DiSaia; Bradley J. Monk; Elizabet 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 1 views

## Abstract ## BACKGROUND A prospective study was undertaken within the Gynecologic Oncology Group to determine whether serum levels of soluble tumor necrosis factor receptors I (sTNFR‐I) and II (sTNFR‐II), alone or in combination with CA 125, were associated with clinicopathologic characteristics

Combination benefit of treatment with th

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis

✍ Alison M. Bendele; Elizabeth S. Chlipala; Jon Scherrer; Janet Frazier; Gina Senn 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 695 KB

Objective. To determine the potential for additive or synergistic effects of combination therapy with the recombinant anticytokine agents interleukin-1 receptor antagonist (IL-1Ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI) in established type II collagen-induced arthri

Increased levels of soluble tumor necros

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

✍ Andrew P. Cope; Deena Gibbons; Fionula M. Brennan; Marc Feldmann; Dan Aderka; Mi 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 815 KB

Elevated Levels of Type II Soluble Tumor

Elevated Levels of Type II Soluble Tumor Necrosis Factor Receptors in the Bronchoalveolar Lavage Fluids of Patients with Sarcoidosis

✍ T. Hino; H. Nakamura; Y. Shibata; S. Abe; S. Kato; H. Tomoike 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 61 KB

Risk of tuberculosis is higher with anti

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

✍ F. Tubach; D. Salmon; P. Ravaud; Y. Allanore; P. Goupille; M. Bréban; B. Pallot- 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 1 views

Role of interleukin-6 in a patient with

Role of interleukin-6 in a patient with tumor necrosis factor receptor–associated periodic syndrome: Assessment of outcomes following treatment with the anti–interleukin-6 receptor monoclonal antibody tocilizumab

✍ Prashantha M. Vaitla; Paul M. Radford; Patrick J. Tighe; Richard J. Powell; Eliz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views